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OBJECTIVES: To estimate the short-term cost per controlled patient with type 2 
diabetes mellitus (T2DM) with liraglutide 1.2mg/day vs. sitagliptin 100mg/day in 
Italy. METHODS: A composite endpoint defined as “HbA1c< 7% AND no weight gain 
AND no hypoglycemia” was adopted to describe the controlled T2DM patient. Based 
on data from a clinical trial (1860-Lira-DPP4) and a meta-analysis (Zinman et al 
2012), the percentage of patients achieving the composite endpoint after 26 and 52 
weeks with liraglutide and sitagliptin were obtained. In addition, responder rates 
after 78 weeks were obtained for patients switching at 52 weeks from sitagliptin to 
liraglutide and a hypothetical cohort continuing on sitagliptin. Treatment cost was 
calculated from the perspective of the Italian National Health System over a 26-, 
52- and 78-week time horizon. The cost-effectiveness primary outcome was the cost 
per patient achieving the composite endpoint. RESULTS: Despite a daily medica-
tion cost ratio of 2.30 between liraglutide and sitagliptin, after 26 weeks liraglutide 
resulted in a lower cost per controlled patient, both with efficacy data extracted from 
the clinical trial (€ 1,460 vs. € 1,820) and from a meta-analysis of available liraglutide 
trials (€ 1,593 vs. € 2,234). At 52 weeks, liraglutide cost per controlled patient is also 
slightly lower than with sitagliptin (€ 2,627 vs. € 2,649). At 78 weeks, in patients who 
have switched from sitagliptin to liraglutide at 52 weeks, the cost per controlled 
patient is lower than that of the hypothetical group of patient controlled with 78 
weeks of continued sitagliptin treatment (€ 2,889 vs. € 3,970). CONCLUSIONS: These 
results indicate that, due to higher effectiveness, liraglutide 1.2mg/day is associated 
with better cost-effectiveness results than sitagliptin 100mg/day after 26 and 52 
weeks. Moreover, switching patients from sitagliptin after 52 weeks to liraglutide 
might result in a clinical benefit that may lower the cost per controlled patient with 
respect to 78-weeks of continued sitagliptin treatment.
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OBJECTIVES: T2DM is a chronic, progressive disease and proper economic evalua-
tion of alternative treatment interventions requires economic modeling over long 
time horizons. As currently available treatments cannot halt disease progression, 
most patients eventually require therapy intensification to meet HbA1c goals. This 
analysis explores the impact of commonly used intensification assumptions on cost-
effectiveness estimates using simulations of canagliflozin (CANA) versus maximally-
titrated glimepiride (GLIM) in patients with uncontrolled HbA1c on metformin in the 
US. METHODS: ECHO-T2DM, a validated micro-simulation model, was used to simu-
late 30-year outcomes and costs associated with using CANA 100 or 300mg versus 
GLIM as add-on to metformin. Patient characteristics, treatment effects, and adverse 
event rates were sourced from a previously reported head-to-head trial. Health utili-
ties and unit costs were sourced from the literature. Two types of treatment inten-
sification triggers were modeled: when HbA1c exceeds a target threshold, and after 
a fixed amount of time. Treatment was intensified first by adding basal insulin and 
then prandial insulin, both titrated to maintain HbA1c control (up to pre-specified 
maximum doses). A simulation with no intensification was also performed. RESULTS: 
Incremental cost-effectiveness ratios (ICERs) for treatment strategies starting with 
CANA 100 and 300mg versus GLIM with insulin rescue at HbA1c > 7.0% were $29,032 
and $22,106, respectively, largely driven by CANA’s ability to keep HbA1c controlled 
longer, thus delaying insulin initiation. Using a fixed (and equal) time on CANA and 
GLIM (5 and 10 years) favored GLIM by eliminating this benefit, yielding higher ICERs. 
The extreme case of no rescue therapy artificially inflated complication costs in both 
arms, since HbA1c drifts unabated upwards. CONCLUSIONS: Assumptions about 
treatment intensification matter. Unrealistic assumptions like fixing time on agents 
or omitting intensification had large effects, as ICERs depend on how downstream 
treatment choices are modeled. Consumers of T2DM economic evaluations should 
therefore consider these assumptions carefully.
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OBJECTIVES: People aged ≥ 65 years with T2DM contribute significantly to the 
increasing rate of health care utilization. CANA, an agent that inhibits sodium glu-
cose co-transporter 2 (SGLT2), and SAXA, a dipeptidyl peptidase-4 inhibitor, have 
provided meaningful HbA1c reductions when used as monotherapy and as add-
on to other antihyperglycemic agents in older patients. This analysis estimates 
the cost-effectiveness of CANA 100 or 300 mg versus SAXA 5 mg in patients with 
T2DM aged ≥ 65 years in the Canadian setting. METHODS: ECHO-T2DM was used to 
simulate outcomes associated with using CANA versus SAXA as an add-on therapy 
in patients with T2DM aged ≥ 65 years. As head-to-head data were unavailable, an 
indirect comparison (IC) was performed using published data on SAXA 5 mg and 
results from a post hoc analysis of CANA data where possible (HbA1c and weight). 
IC estimates were calculated for those inadequately controlled on a mix of different 
background therapies (lifestyle intervention alone or combination with metformin, 
metformin plus sulfonylurea, or metformin plus pioglitazone). For other biomarkers 
(ie, cholesterol, systolic blood pressure) and adverse event rates, SAXA 5 mg values 
were assumed to be equal to those of placebo in the post hoc analysis. The post 
thiazolidinediones (Met-TZD), metformin plus meglitidine (Met-MEG), and met-
formin plus DPP-4 inhibitors (DPP4I). Five triple therapy cohorts included: a refer-
ence - Met plus insulin; four comparisons - Met-SU-ACA, Met-SU-TZD, Met-SU-MEG 
and Met-SU-DPP4I. These combinations of cohorts were constructed because they 
were most commonly prescribed in Taiwan. Each comparison subject was 1:1 pro-
pensity scores matched to the reference subject on demographics and comorbidity. 
The effectiveness outcomes were cardiovascular complication (CVD) and survival. 
Only direct medical costs were included (expressed in 2014 US dollars). Markov 
chain models from the CDC Diabetes Cost-effectiveness group were adapted to 
project lifetime outcomes with discounted at 3% per annum. Bootstrapping tech-
nique was applied to account for uncertainty in analyses. RESULTS: The average 
age-gender weighted lifetime costs were $94,112.5, of which 61% was attributed to 
diabetic complications. The estimated lifetime CVD risk was 34%, with the highest 
in Met-SU and the lowest in Met-TZD (40% vs. 31%, p< .05) in the dual therapy, while 
in the triple therapy, the users of Met-SU-DPP4I had lower CVD risk as compared 
to Met-Insulin (44% vs. 58%, p< .01). Average annual medical costs in Met-SU-DPP4I 
were highest, due to high drug acquisition price. However, over lifetime, Met-Insulin 
had the highest spending, most attributed to managing diabetic complications. 
Sensitivity analyses demonstrated the most cost-effectiveness of Met-TZD use in 
dual therapy and that of Met-SU-DPP4I use in triple therapy. CONCLUSIONS: The 
results would inform clinical selection of add-on therapy in the patients with inad-
equately controlled by metformin.
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OBJECTIVES: Weight management via healthy eating and increased physical activ-
ity is a cornerstone of T2DM treatment. CANA, an agent that inhibits sodium 
glucose co-transporter 2, decreases glucose levels by lowering the renal thresh-
old for glucose excretion thereby increasing urinary glucose excretion (UGE), 
which generally leads to reductions in weight and systolic blood pressure (SBP). 
Dipeptidyl peptidase-4 inhibitors such as SITA are not associated with weight loss 
or SBP reductions, so assumptions about utility changes associated with weight 
changes may be a key driver of economic evaluations that compare these agents. 
The objective of this analysis was to examine the impact of alternative weight-
related utility change estimates on the cost-effectiveness of CANA 300 mg versus 
SITA 100 mg using results from a clinical study in patients inadequately controlled 
with metformin plus sulfonylurea. METHODS: The ECHO-T2DM, a validated model 
of T2DM, was used to estimate the cost-effectiveness of CANA versus SITA as an 
add-on to dual therapy over 40 years using 3 different sources for weight-related 
utility changes: (A) CODE-2, (B) CADTH, and (C) new Canada-specific estimates 
that distinguish between weight gain and weight loss. Patient characteristics, 
treatment effects, and adverse events were sourced from the aforementioned 
clinical study. A willingness-to-pay threshold of $50,000 was used and net mon-
etary benefits (NMBs) were calculated. RESULTS: CANA dominated SITA in all 
3 cases. The NMBs for the comparison of CANA versus SITA varied from $4,500 
(CADTH) to $6,124 (CODE-2). The NMB using the new Canada-specific estimates 
was $4,690. CONCLUSIONS: These results illustrate that weight-related utility 
changes are important drivers in cost-effectiveness assessments of agents with 
different weight profiles. The finding of sizable health economic benefits from 
using CANA versus SITA as an add-on to dual therapy was consistent across a 
wide range of weight change–related utility values, however.
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OBJECTIVES: CANA, an agent that inhibits sodium glucose co-transporter 2, 
decreases glucose levels by lowering the renal threshold for glucose excretion, 
thereby resulting in an increase in urinary glucose excretion (UGE). This increase 
in UGE reduces weight, as well as systolic blood pressure (SBP). In contrast, dipep-
tidyl peptidase-4 inhibitors such as SITA lower glucose but are not associated with 
weight loss or a reduction in SBP. The objective of this analysis was to evaluate the 
cost-effectiveness of CANA 100 and 300 mg versus SITA 100 mg in dual therapy 
and triple therapy as an add-on to metformin and as an add-on to metformin 
plus sulphonylurea, respectively, from the Spanish National Health System per-
spective. METHODS: The IMS CORE Diabetes Model was used to evaluate the cost-
effectiveness of CANA 100 and 300 mg versus SITA using Spanish-specific utilities 
and cost data. Direct costs were reported in euros and an annual discount rate 
of 3% was applied on costs and effects. The time horizon used for the economic 
evaluation was 40 years to reflect the chronic nature of the disease. Patient char-
acteristics, treatment effects, and safety were sourced from direct comparisons 
using clinical trial data for CANA. Results were compared with the willingness-
to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: Results sug-
gest that CANA 100 mg dominates SITA in dual therapy and in triple therapy, with 
estimated quality-adjusted life year (QALY) gains of 0.027 and 0.057, respectively. 
CANA 300 mg is cost-effective compared to SITA in dual and triple therapy, with a 
cost-effectiveness ratio below the WTP threshold in Spain; QALY gains were 0.060 
and 0.075, respectively. CONCLUSIONS: These results suggest that adding CANA 
100 or 300 mg instead of SITA in patients inadequately controlled on metformin 
or metformin plus sulphonylurea would result in more efficient use of healthcare 
resources in the Spanish setting.
